Table Graph
      published meta-analysis   sensitivity analysis   studies

bamlanivimab monotherapy in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBLAZE-2 US (Cohen), 2021 0.83 [0.25; 2.73] 0.83[0.25; 2.73]BLAZE-2 US (Cohen), 202110%966NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsBLAZE-2 US (Cohen), 2021 0.43 [0.28; 0.67] 0.43[0.28; 0.67]BLAZE-2 US (Cohen), 202110%961NAnot evaluable adverse eventsdetailed resultsBLAZE-2 US (Cohen), 2021 2.02 [1.54; 2.64] 2.02[1.54; 2.64]BLAZE-2 US (Cohen), 202110%1,175NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-04-20 09:38 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 742 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons